Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Oct 20, 5:21 PMAlcon to acquire Neurotech Pharmaceuticals for $550 million, adding ENCELTO, only FDA-approved MacTel Type 2 treatment
Index
-
Market Cap
32.39B
Enterprise Value
36.23B
Income
643.00M
Sales
10.86B
Book/sh
44.67
Cash/sh
3.02
Employees
25942
IPO
Apr 09, 2019
P/E
51.51
Forward P/E
17.02
PEG
1.28
P/S
2.98
P/B
1.50
P/C
22.24
P/FCF
18.61
EV/EBITDA
14.70
EV/Sales
3.34
Quick Ratio
1.30
Current Ratio
2.09
Debt/Eq
0.25
LT Debt/Eq
0.22
Option/Short
Yes / Yes
EPS (ttm)
1.30
EPS next Y
3.95
EPS next Q
0.88
EPS this Y
13.67%
EPS next Y
13.07%
EPS next 5Y
13.28%
EPS past 3/5Y
42.85% -
Sales past 3/5Y
6.06% 8.77%
EPS Y/Y TTM
-39.47%
Sales Y/Y TTM
8.34%
EPS Q/Q
-100.00%
Sales Q/Q
8.74%
Insider Own
0.11%
Insider Trans
0.00%
Inst Own
52.93%
Inst Trans
0.11%
ROA
2.06%
ROE
2.94%
ROIC
2.45%
Gross Margin
56.85%
Oper. Margin
10.93%
Profit Margin
5.92%
SMA20
3.51%
SMA50
-1.15%
SMA200
-7.00%
Trades
Shs Outstand
483.40M
Shs Float
481.57M
52W High
87.64 -23.35%
52W Low
61.83 8.64%
Volatility
1.60% 1.54%
ATR (14)
1.26
RSI (14)
56.22
Beta
0.89
Rel Volume
0.05
Avg Volume
1.76M
Volume
4,669
Perf Week
0.89%
Perf Month
2.73%
Perf Quarter
-1.08%
Perf Half Y
-11.45%
Perf YTD
-14.76%
Perf Year
-12.07%
Perf 3Y
-7.36%
Perf 5Y
-17.99%
Perf 10Y
-
Prev Close
67.43
Price
67.17
Change %
-0.38%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Duplan SergioOfficerFeb 26 '26Proposed Sale86.5415,0001,298,128Feb 26 03:55 PM
Attias LaurentOfficerFeb 26 '26Proposed Sale86.912,412209,634Feb 26 11:22 AM
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the Surgical and Vision Care segments. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner in 1945 and is headquartered in Geneva, Switzerland.
CEO & DirectorMr. David J. Endicott
Senior VP & CFOMr. Timothy C. Stonesifer
Senior VP & COOMr. Ian Bell
Chief Accounting OfficerMargaret Buckley
SVP of Global Research & Development and Chief Scientific OfficerDr. Franck Leveiller Ph.D.